A new trading day began on Friday, with Vistagen Therapeutics Inc (NASDAQ: VTGN) stock price up 3.41% from the previous day of trading, before settling in for the closing price of $3.23. VTGN’s price has ranged from $1.90 to $3.59 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 35.63%. Meanwhile, its annual earnings per share averaged 2.99%. With a float of $27.73 million, this company’s outstanding shares have now reached $29.28 million.
Vistagen Therapeutics Inc (VTGN) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Vistagen Therapeutics Inc is 9.63%, while institutional ownership is 42.24%.
Vistagen Therapeutics Inc (VTGN) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.42 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.83% during the next five years compared to 35.63% growth over the previous five years of trading.
Vistagen Therapeutics Inc (NASDAQ: VTGN) Trading Performance Indicators
Here are Vistagen Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 146.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.58, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of Vistagen Therapeutics Inc (VTGN)
Looking closely at Vistagen Therapeutics Inc (NASDAQ: VTGN), its last 5-days average volume was 0.34 million, which is a jump from its year-to-date volume of 0.26 million. As of the previous 9 days, the stock’s Stochastic %D was 52.57%.
During the past 100 days, Vistagen Therapeutics Inc’s (VTGN) raw stochastic average was set at 85.71%, which indicates a significant increase from 68.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.21 in the past 14 days, which was higher than the 0.17 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.68, while its 200-day Moving Average is $2.61. However, in the short run, Vistagen Therapeutics Inc’s stock first resistance to watch stands at $3.43. Second resistance stands at $3.52. The third major resistance level sits at $3.66. If the price goes on to break the first support level at $3.20, it is likely to go to the next support level at $3.05. Should the price break the second support level, the third support level stands at $2.96.
Vistagen Therapeutics Inc (NASDAQ: VTGN) Key Stats
With a market capitalization of 102.47 million, the company has a total of 30,680K Shares Outstanding. Currently, annual sales are 490 K while annual income is -51,420 K. The company’s previous quarter sales were 240 K while its latest quarter income was -15,100 K.
